Adma Biologics (ADMA) Long-Term Debt Repayments (2016 - 2025)
Historic Long-Term Debt Repayments for Adma Biologics (ADMA) over the last 12 years, with Q3 2025 value amounting to $2.5 million.
- Adma Biologics' Long-Term Debt Repayments fell 9166.67% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.1 million, marking a year-over-year increase of 1723.37%. This contributed to the annual value of $60.0 million for FY2024, which is 6216.52% down from last year.
- According to the latest figures from Q3 2025, Adma Biologics' Long-Term Debt Repayments is $2.5 million, which was down 9166.67% from $30.0 million recorded in Q4 2024.
- In the past 5 years, Adma Biologics' Long-Term Debt Repayments ranged from a high of $158.6 million in Q4 2023 and a low of $2.5 million during Q3 2025
- Over the past 4 years, Adma Biologics' median Long-Term Debt Repayments value was $30.0 million (recorded in 2024), while the average stood at $64.2 million.
- As far as peak fluctuations go, Adma Biologics' Long-Term Debt Repayments crashed by 8108.26% in 2024, and later tumbled by 9166.67% in 2025.
- Adma Biologics' Long-Term Debt Repayments (Quarter) stood at $100.0 million in 2022, then surged by 58.58% to $158.6 million in 2023, then plummeted by 81.08% to $30.0 million in 2024, then crashed by 91.67% to $2.5 million in 2025.
- Its Long-Term Debt Repayments stands at $2.5 million for Q3 2025, versus $30.0 million for Q4 2024 and $30.0 million for Q3 2024.